The Biology of Eosinophils: How They Damage Tissues and Affect Platelets
At a Glance
High eosinophil levels can damage blood vessels and the heart by releasing inflammatory proteins, which may increase clotting and cause organ injury. Inflammation can raise platelet counts, while clotting or other processes can lower them; testing helps identify the cause.
When your body produces too many eosinophils, it is not just a change in your blood counts; it is a shift in your internal biology. Eosinophils are a type of white blood cell meant to fight parasites and handle allergies, but when they are overproduced and over-activated, they can become “toxic” to your own tissues [1][2].
Understanding how these cells cause damage and how doctors distinguish between the different conditions they cause can help you navigate your care more effectively.
The Biology of Tissue Damage
Eosinophils contain small “granules” filled with powerful proteins, including Major Basic Protein (MBP) and Eosinophil Cationic Protein (ECP) [1]. When eosinophils are activated, they release these proteins through a process called degranulation.
Damage to the Blood Vessels and Heart
These granule proteins can directly injure the endothelium, the delicate inner lining of your blood vessels [3][4]. This injury does more than just damage the vessel; it increases the tendency for clot formation, making your blood much more likely to form dangerous clots [5].
In the heart, this process can sometimes follow three phases, though this is not an inevitable progression for every patient:
- Infiltration: Eosinophils enter the heart muscle (myocardium) and the inner lining of the heart [6].
- Thrombosis: Clots may form along the damaged heart walls [7].
- Fibrosis: Over time, the damage can lead to scarring, which can stiffen the heart and affect its ability to pump [8].
Eosinophil Extracellular Traps (EETs)
In addition to degranulation, researchers are actively studying how eosinophils can release their own DNA into the surrounding tissue to form “traps” called EETs [9]. While these traps are meant to catch bacteria, in chronic disease, they may contribute to inflammation and the formation of blood clots in the vessels [10]. (Note: this is an emerging scientific mechanism, not a routine clinical test).
The Link Between Eosinophils and Platelets
It is common for patients with high eosinophils to also have abnormal platelet counts. This connection typically happens through two different biological routes:
- Reactive Thrombocytosis (High Platelets): When your body is in a high state of inflammation, your immune system releases “messenger” proteins like Interleukin-6 (IL-6). This cytokine signals your liver to produce thrombopoietin, the hormone that tells your bone marrow to make more platelets [11]. In this case, high platelets are a “reactive” sign of the overall inflammation in your body [12].
- Platelet Consumption (Low Platelets): If the eosinophils are causing widespread clotting (thrombosis) or a condition called Thrombotic Microangiopathy (TMA), your body may use up its supply of platelets faster than it can make them [13][14]. This “consumption” leads to thrombocytopenia (low platelets) [15]. However, it is important to remember that low platelets can also result from immune destruction, medications, or marrow problems, and must be evaluated carefully by a specialist.
The Differential Diagnosis: What Is It?
Because high eosinophils can look similar across many diseases, doctors use a “differential diagnosis” to narrow down the cause.
1. EGPA (Eosinophilic Granulomatosis with Polyangiitis)
Formerly called Churg-Strauss syndrome, EGPA is a form of vasculitis (blood vessel inflammation). Doctors look for the full clinical and imaging picture, often including a combination of asthma, nasal polyps, and nerve pain [16][17]. About one-third of patients test positive for ANCA antibodies, but a negative test does not rule out EGPA [18][19].
2. HES (Hypereosinophilic Syndrome)
HES is diagnosed when eosinophils are high (over 1,500/µL) and there is clear evidence of organ damage, and other causes have been excluded [20][21]. Note that EGPA and HES can overlap clinically, and the absence of a classic EGPA pattern is not by itself enough to establish HES.
3. Clonal Myeloid Neoplasms
This is a “primary” bone marrow disorder where a genetic mutation causes the marrow to overproduce eosinophils. Doctors check for specific genetic markers, such as PDGFRA, PDGFRB, FGFR1, or JAK2 [22][20]. If one of these is found, the treatment is often very different—imatinib is particularly effective for PDGFRA and some PDGFRB fusions, whereas FGFR1 and JAK2 require different specialist-directed strategies [22].
4. IgG4-Related Disease
This is a newer category of inflammatory disease that can cause high eosinophils and tumor-like swelling in organs like the pancreas or salivary glands [23]. It is often associated with high levels of IgG4 in the blood, though this is neither required nor specific, and diagnosis relies on appropriate tissue biopsy findings [24][25].
Common questions in this guide
How can high eosinophils damage tissues?
What causes high or low platelets when eosinophils are elevated?
How do doctors tell EGPA from hypereosinophilic syndrome?
What tests may be used to find the cause of eosinophilia and platelet changes?
Can eosinophilia affect the heart?
Why are PDGFRA and other genetic markers important?
Get notified when new evidence is published on platelet abnormalities with eosinophilia and immune-mediated inflammatory disease.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (25)
- 1
Experimental Modeling of Eosinophil-Associated Diseases.
Upparahalli Venkateshaiah S, Manohar M, Kandikattu HK, Mishra A
Methods in molecular biology (Clifton, N.J.) 2021; (2241()):275-291 doi:10.1007/978-1-0716-1095-4_21.
PMID: 33486743 - 2
Eosinophil-Related Disease and the Skin.
Leiferman KM, Peters MS
The journal of allergy and clinical immunology. In practice 2018; (6(5)):1462-1482.e6 doi:10.1016/j.jaip.2018.06.002.
PMID: 29902530 - 3
[ACUTE VISION LOSS ASSOCIATED WITH HYPEREOSINOPHILIC SYNDROME].
Man Peles I, Goldenberg-Cohen N
Harefuah 2022; (161(10)):603-605.
PMID: 36315204 - 4
Case report: Serious unexpected vascular events in two patients with lymphocytic variant hypereosinophilic syndrome.
Torcida N, Casalino G, Bondue A, et al.
Frontiers in cardiovascular medicine 2023; (10()):1256862 doi:10.3389/fcvm.2023.1256862.
PMID: 37829688 - 5
Differential roles of eosinophils in cardiovascular disease.
Xu J, Guo J, Liu T, et al.
Nature reviews. Cardiology 2025; (22(3)):165-182 doi:10.1038/s41569-024-01071-5.
PMID: 39285242 - 6
Eosinophilic myocarditis and hypereosinophilic syndrome.
Boussir H, Ghalem A, Ismaili N, El Ouafi N
Journal of the Saudi Heart Association 2017; (29(3)):211-213 doi:10.1016/j.jsha.2016.11.001.
PMID: 28652675 - 7
The Cleveland Clinic experience of eosinophilic myocarditis in the setting of hypereosinophilic syndrome: demographics, cardiac imaging, and outcomes.
Reeder M, Okushi Y, Lo Presti Vega S, et al.
Cardiovascular diagnosis and therapy 2024; (14(6)):1122-1133 doi:10.21037/cdt-24-347.
PMID: 39790190 - 8
Hypereosinophilic syndrome: considerations for the cardiologist.
Bondue A, Carpentier C, Roufosse F
Heart (British Cardiac Society) 2022; (108(3)):164-171 doi:10.1136/heartjnl-2020-317202.
PMID: 34172539 - 9
Eosinophil ETosis-Mediated Release of Galectin-10 in Eosinophilic Granulomatosis With Polyangiitis.
Fukuchi M, Kamide Y, Ueki S, et al.
Arthritis & rheumatology (Hoboken, N.J.) 2021; (73(9)):1683-1693 doi:10.1002/art.41727.
PMID: 33750029 - 10
Direct Fast Scarlet and Congo Red Staining in Identification of Eosinophils and Their Cell-Free Granules in Cardiac Tissue.
Kumaki T, Abe T, Kashimura T, et al.
International heart journal 2025; (66(6)):968-977 doi:10.1536/ihj.25-317.
PMID: 41320336 - 11
Neutrophil-derived S100 calcium-binding proteins A8/A9 promote reticulated thrombocytosis and atherogenesis in diabetes.
Kraakman MJ, Lee MK, Al-Sharea A, et al.
The Journal of clinical investigation 2017; (127(6)):2133-2147.
PMID: 28504650 - 12
Reactive thrombocytosis in acute infectious diseases: Prevalence, characteristics and timing.
Schattner A, Kadi J, Dubin I
European journal of internal medicine 2019; (63()):42-45 doi:10.1016/j.ejim.2019.02.010.
PMID: 30795883 - 13
Rare Case of a Young Male Presented with Abdominal Pain, Solid Colon Tumors, and Eosinophilia, Followed by Tremendous Thromboembolic Complications and Eventually Diagnosed with Idiopathic Hypereosinophilic Syndrome.
Zemleduch T, Czapla A, Kimla P, Kudliński B
Case reports in medicine 2022; (2022()):1424749 doi:10.1155/2022/1424749.
PMID: 35646123 - 14
Complement Factor I Gene Variant in an Atypical Hemolytic Uremic Syndrome Triggered by Hypereosinophilia Syndrome.
Banjongjit A, Kittanamongkolchai W, Kanjanabuch T
Nephron 2023; (147(11)):701-706 doi:10.1159/000531879.
PMID: 37611541 - 15
Microangiopathic Anemia.
Bommer M, Bloehdorn J
Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie 2025; (52(4)):259-270 doi:10.1159/000544724.
PMID: 40809448 - 16
[Eosinophilic granulomatosis with polyangiitis: a review article].
Schindler V, Venhoff N
Laryngo- rhino- otologie 2024; (103(10)):705-714 doi:10.1055/a-2214-1669.
PMID: 38964344 - 17
Red flags for clinical suspicion of eosinophilic granulomatosis with polyangiitis (EGPA).
Solans-Laqué R, Rúa-Figueroa I, Blanco Aparicio M, et al.
European journal of internal medicine 2024; (128()):45-52 doi:10.1016/j.ejim.2024.06.008.
PMID: 38880725 - 18
International Consensus on Antineutrophil Cytoplasm Antibodies Testing in Eosinophilic Granulomatosis with Polyangiitis.
Moiseev S, Bossuyt X, Arimura Y, et al.
American journal of respiratory and critical care medicine 2020; (202(10)):1360-1372 doi:10.1164/rccm.202005-1628SO.
PMID: 32584187 - 19
Eosinophilic granulomatosis with polyangiitis - Advances in pathogenesis, diagnosis, and treatment.
Fijolek J, Radzikowska E
Frontiers in medicine 2023; (10()):1145257 doi:10.3389/fmed.2023.1145257.
PMID: 37215720 - 20
[Eosinophilia: hypereosinophilic syndrome vs. eosinophilic granulomatosis with polyangiitis].
Holle JU, Moosig F
Zeitschrift fur Rheumatologie 2023; (82(4)):307-320 doi:10.1007/s00393-023-01345-2.
PMID: 37099180 - 21
Causes of hypereosinophilia in 100 consecutive patients.
Moller D, Tan J, Gauiran DTV, et al.
European journal of haematology 2020; (105(3)):292-301 doi:10.1111/ejh.13437.
PMID: 32364630 - 22
Eosinophilic Myocarditis.
Cheung CC, Constantine M, Ahmadi A, et al.
The American journal of the medical sciences 2017; (354(5)):486-492 doi:10.1016/j.amjms.2017.04.002.
PMID: 29173361 - 23
Coexistence of IgG4-related disease and ANCA-associated vasculitis: case report and review of the literature.
Korkmaz C, Yıldırım R, Dinler M, Cansu DU
Rheumatology international 2024; (44(3)):557-572 doi:10.1007/s00296-023-05419-x.
PMID: 37634133 - 24
A case of eosinophilic granulomatosis with polyangiitis complicated with a similar condition to IgG4 related lung disease.
Zhou L, Cao F, Fan S, et al.
BMC pulmonary medicine 2019; (19(1)):154 doi:10.1186/s12890-019-0917-4.
PMID: 31426769 - 25
Eosinophilic granulomatosis with polyangiitis exhibits T cell activation and IgG4 immune response in the tissue; comparison with IgG4-related disease.
Kubo S, Kanda R, Nawata A, et al.
RMD open 2022; (8(1)) doi:10.1136/rmdopen-2021-002086.
PMID: 35260476
This page explains eosinophilia, tissue injury, and platelet changes for informational purposes only and does not constitute medical advice. A hematologist or other specialist should interpret your results and symptoms.